$PEPG
PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
Healthcare
Sector
Biotechnology
Industry
James G. McArthur
CEO
79
Employees
$4.70
Current Price
$444.73M
Market Cap
Insider Activity Statistics
Aggregated buying and selling activity by time period
| Period | Type | Insiders | Transactions | Value | Shares | Buy/Sell Ratio |
|---|---|---|---|---|---|---|
| 1 week | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 2 weeks | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 1 month | Buys | 0 | 0 | - | - | All Sells |
| Sells | 3 | 6 | $57,572.85 | 9,238 | ||
| 2 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 3 | 6 | $57,572.85 | 9,238 | ||
| 3 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 3 | 6 | $57,572.85 | 9,238 | ||
See activity going back 12 months โ create a free account | ||||||
Insider Transactions
Recent purchases and sales by company insiders
| Date | Insider | Type | Shares | Price | Value | Actions |
|---|---|---|---|---|---|---|
| Mar 4, 2026 | STRECK PAUL EVP, Head of R&D | Sale | 1,832 | $6.23 | $11,413.36 | View Details |
| Mar 4, 2026 | STRECK PAUL EVP, Head of R&D | Sale | 47 | $6.29 | $295.54 | View Details |
| Mar 4, 2026 | Donnelly Noel Chief Financial Officer | Sale | 2,032 | $6.23 | $12,659.36 | View Details |
| Mar 4, 2026 | Donnelly Noel Chief Financial Officer | Sale | 52 | $6.33 | $328.90 | View Details |
| Mar 4, 2026 | McArthur James G Director | Sale | 5,144 | $6.23 | $32,047.12 | View Details |
| Mar 4, 2026 | McArthur James G Director | Sale | 131 | $6.33 | $828.58 | View Details |
5 more transactions available โ create a free account to see 12 months of history | ||||||
Upcoming Earnings
Scheduled earnings reports
No upcoming earnings scheduled
Past Earnings
Historical earnings results
EPS
Estimated-$0.38
ActualN/A
Revenue
EstimatedN/A
ActualN/A
Related Activity
Cross-company insider connections and cluster buy signals
Insiders Also Active At
Insiders at this company also hold positions or have traded at these companies:
$CDTX โ Cidara Therapeutics, Inc.via RA CAPITAL MANAGEMENT, L.P.$WVE โ Wave Life Sciences Ltd.via RA CAPITAL MANAGEMENT, L.P.$CLYM โ Climb Bio, Inc.via RA CAPITAL MANAGEMENT, L.P.$SGP โ SpyGlass Pharma, Inc. Common Stockvia RA CAPITAL MANAGEMENT, L.P.$HOWL โ Werewolf Therapeutics, Inc.via RA CAPITAL MANAGEMENT, L.P.$TYRA โ Tyra Biosciences, Inc.via RA CAPITAL MANAGEMENT, L.P.$MLYS โ Mineralys Therapeutics, Inc.via RA CAPITAL MANAGEMENT, L.P.$BCAX โ Bicara Therapeutics Inc.via RA CAPITAL MANAGEMENT, L.P.